Translating Mechanistic Insight into Confident Predictions
This Day 2 track at Certainty will focus on current advances and practical applications of physiologically based pharmacokinetic (PBPK) modeling. Scientific sessions will highlight key areas where PBPK informs decision-making across drug development, including first-in-human (FIH) dose prediction, formulation design, drug-drug interaction assessment, and dose optimization in specific populations.
Designed for participants across all levels of PBPK expertise, this track will strengthen confidence in model-informed drug development and regulatory interactions.
Through expert presentations and real-world case studies, this track will provide:
- A deeper understanding of emerging best practices in PBPK modeling
- Actionable insights that can be directly applied to ongoing programs
- An understanding of the strategic value of PBPK modeling in identifying risks early, informing decisions, and preventing avoidable delays.
April 15, 2026
Agenda
8:00 – 9:00
Breakfast & Badge Pick Up
9:00 – 10:30
Morning session 1
10:30 – 11:00
Morning break
11:00 – 12:30
Morning session 2
12:30 – 2:00
Lunch and learns
2:00 – 3:30
Afternoon session
3:30 -3:45
Close of day
As a QSP Summit at Certainty attendee you may also be interested in this session
Modeling and Simulation from Preclinical to Approval
Join us on Day 1 of Certainty to learn how empirical PK/PD methods like NCA and popPK are complementing in silico approaches like PBPK and QSP to answer the most daunting challenges in development, from optimal first-in-human dosing to presenting clin pharm evidence effectively in your NDA or BLA.
Reserve your spot
Reserve your spot for the Certainty US 2026 customer event for exclusive access to the Certara community of experts, industry leaders, and peers as we collectively explore the latest innovations and opportunities to bring greater certainty to drug discovery and development.
